Tuoyi (Toripalimab) – Nasopharyngeal Carcinoma | HongKong DengYue Medicine

Toripalimab Application Scope

Approved for treatment of nasopharyngeal carcinoma, either in combination therapy or monotherapy. Also indicated in China for melanoma.

Broad potential across multiple tumor types, including lung and digestive cancers (under study).

Toripalimab Characteristics

• Ingredients:
  Toripalimab‑tpzi (recombinant humanized anti–PD‑1 monoclonal antibody)

  Properties:
  Used to block PD‑1 receptor, enabling enhanced anti-tumor immune response. Orphan drug for NPC.

  Packaging Specification:
  Single-dose vial containing 240 mg antibody in 6 mL solution

  Storage:
  2–8 °C, protect from light; do not freeze or shake. Diluted solutions: store up to 24 h refrigerated or 8 h at room temperature.

  Expiry Date:
  Refer to vial label

  Executive Standard:
  To be updated per local pharmacopeia or regulatory guidelines

  Approval Number:
  (China NMPA), Hong Kong Drug Office, FDA (U.S.), EMA (Europe) approvals via Loqtorzi/VTAMA labels

• Date of Revision:
  [Insert latest revision date]

  Manufacturer:
  Shanghai Junshi Biosciences Co., Ltd. (development), TopAlliance Biosciences Inc. (licensing), distributed as Loqtorzi in Hong Kong

Guidelines for the Use of Toripalimab

• Dosage and Administration:

  • Combination (NPC): 240 mg IV every 3 weeks with cisplatin and gemcitabine, until disease progression, unacceptable toxicity, or up to 24 months.

  • Monotherapy (NPC): 3 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity

  • Melanoma (China): Refer to label [not detailed here]

• Adverse Reactions:

  • Common Adverse Reactions: Nausea, vomiting, decreased appetite, constipation, diarrhea, rash, fever, cough, peripheral neuropathy, muscle/joint pain, fatigue, hypothyroidism, upper respiratory infection, insomnia, dizziness, malaise

  • Serious Adverse Reactions: Grade ≥3 immune-mediated events: pneumonitis, colitis, hepatitis, endocrinopathies (hypothyroidism, adrenal insufficiency, hypophysitis), nephritis, severe skin reactions (SJS/TEN), infusion-related reactions, bleeding, metabolic disturbances​

• Contraindications: None listed explicitly in current FDA label

• Precautions:

  •  Monitor for immune-mediated conditions—incidence of serious events warrant dose withholding or discontinuation
    
  • Infusion-related reactions—monitor closely, especially during first infusion
  • Pregnancy: Use effective contraception during and for 4 months post-treatment
  • Lactation: Unknown excretion; consult physician​

Toripalimab Interactions

• No major drug–drug interactions noted; caution when co-administering with other immunomodulators or prior radiation therapy. Administer prior to chemotherapy if co-dosed.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.